Elevating cancer care: scientific director’s view on IEO’s Proton Therapy Expansion

Описание: Roberto Orecchia, Scientific Director of the European Institute of Oncology (IEO) in Milan, Italy, and Director of Imaging & Radiation Sciences, discusses IEO’s strategic decision to acquire the ProteusONE proton therapy system to expand the center’s radiotherapy services. The proton therapy acquisition not only “enhanced the institute’s local and international reputation” but also generated a positive ripple effect on conventional photon radiotherapy services and other possible alternative treatments.

Dr. Orecchia emphasizes how pediatric tumors but also many other types of cancers benefit from the high precision of proton therapy. He also discusses global access disparities, noting that proton centers remain scarce in middle- and low-income regions despite high cancer incidence. Dr. Orecchia underlines the importance of selecting a forward-looking partner: IBA’s ProteusONE seamlessly integrated into IEO’s existing department, and IBA’s commitment to R&D promises upcoming innovations like DynamicARC* and future FLASH therapy.

Key Highlights

00:17 Introduction: Roberto Orecchia’s role at IEO and CNAO

00:57 Why IEO invested in proton therapy for innovation and reputation

01:23 Reputation boost: local, national, and global attractiveness

02:24 Expanding indications: beyond pediatrics to diverse tumor types

03:25 Addressing access gaps: the global distribution challenge

04:04 Partnering with IBA: ProteusONE integration and future R&D


CNAO: the National Center for Oncological Hadrontherapy in Pavia

📚 Want to know more about IBA Proton Therapy? Take a closer look here: https://www.iba-protontherapy.com/

#ProtonTherapy #RadiationTherapy #RadiotherapyServices #ProteusONE #ProtonTherapyCenter #ProtonCenter #PatientCare #RadiationOncology #EuropeanInstituteofOncology #IEO #ScientificDirector #IBAPartnership #MedicalPartnership #MedicalCollaboration #PediatricTumors #DynamicARC #FLASHtherapy


Disclaimer: The statements of the healthcare professional included in this testimonial reflect only his opinion and personal experience. They do not necessarily reflect the opinion of any institution with whom he is affiliated or IBA.

*ConformalFLASH® & DynamicARC® are registered brands of IBA’s Proton Therapy which are currently under research and development. ConformalFLASH® and DynamicARC® will be available for sale when regulatory clearance is received. Due to a continuous research and development program, IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. Some features are under development and may be subject to review by competent authorities.

▬ Learn more ▬▬▬▬▬▬▬▬▬▬▬

Pushing the boundaries of cancer care: Embracing Proton Therapy with ProteusONE
   • Pushing the boundaries of cancer care: Emb...  

360° tour of a proton therapy center with ProteusONE
   • 360° tour of a proton therapy center with ...  

Boosting patient care and institutional growth with Proton Therapy
   • Boosting patient care and institutional gr...  

▬ Follow us ▬▬▬▬▬▬▬▬▬▬▬▬

Discover us on LinkedIn:
  / iba-proton-therapy  

Find us on Facebook:
  / ibatoday  

Subscribe to this YouTube channel:
   / @ibaprotontherapy  

▬ About IBA ▬▬▬▬▬▬▬▬▬▬▬▬

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance."